BUSINESS
AM Naik-backed S3V launches indigenous Transcatheter Aortic Valve Replacement system
TAVR, a minimally invasive alternative to open‑heart surgery for severe aortic stenosis, has become the global standard for elderly and high‑risk patients.
BUSINESS
CDSCO warns pharma companies against promotion of weight-loss drugs, tightens oversight
Any advertisement, direct or indirect, that promotes prescription medicines to the general public, inflates efficacy claims or implies guaranteed weight loss outcomes will be deemed misleading and can invite regulatory action, the regulator has said
BUSINESS
Aster DM targeting 300 bps margin boost, will stick to multi-brand strategy, says Alisha Moopen
Aster DM Healthcare's merger with Blackstone-backed Quality Care moves forward after a 96.68% shareholder vote on March 11, clearing the way for India's third-largest hospital chain
BUSINESS
Granules India looks for M&A as it expands beyond the US, deepens focus on complex generics
To fund this transition and strengthen balance sheet, the company completed a Rs1,762.50 crore capital-raise in February 2026.
BUSINESS
Beyond the price war, Indian drug companies gearing up to win the GLP-1 retention game
Industry analysts say the arrival of these affordable alternatives—expected to be priced at one-third to one-fifth of the innovator's cost.
BUSINESS
Pharma exporters brace for Rs 5,000-crore hit as US-Iran war drives up freight costs
Exporters face steep surcharge of $4,000–$8,000 per shipment, driving up logistics costs for drugmakers heavily dependent on the Gulf and the wider West Asia market
BUSINESS
Swiss CDMO giant Lonza to set up GCC in Hyderabad
The Switzerland‑based company finalized its decision after months of evaluation and discussions with state leadership.
BUSINESS
Hospitals brace for 'soft' quarter as US-Iran war disrupt international travel
West Asia is not just a source market, it is also India’s primary aviation corridor that connects Africa, Central Asia and Europe to India
BUSINESS
Glenmark gets USFDA nod for generic Flovent with 180‑day CGT exclusivity
CGT designations are granted to medicines with limited generic competition, and first‑approved applicants are eligible for six months of exclusivity—an incentive aimed at encouraging development of hard‑to‑copy generics, particularly in categories like inhalation therapies where technical barriers are high.
BUSINESS
US-Iran escalation disrupts vital trade corridors, leaving Indian pharma on edge
India exported $30.47 billion worth of pharmaceuticals in FY25, with around $1.75 billion tied to the Middle East and North Africa region, making the current situation particularly worrying
BUSINESS
Artemis Medicare to raise Rs 700-crore through QIP to triple bed capacity
The Gurugram-based healthcare provider, promoted by entities linked to the Apollo Tyres Group, aims to triple its total bed capacity to between 1,700 and 2,300 by 2029
BUSINESS
Rajeev Raghuvanshi gets one year extension as India’s top drug regulator
The move comes as the government keeps regular recruitment rules for the post in abeyance, signaling a preference for leadership continuity within the Central Drugs Standard Control Organization (CDSCO) amid ongoing regulatory reforms.
BUSINESS
Abbott to distribute Novo Nordisk's semaglutide second brand Extensior in India
The companies announced that Abbott will commercialise the drug in India while Novo Nordisk supplies the molecule, which is globally known as Ozempic.
BUSINESS
GSK study flags low Shingles awareness among older Indians despite rising risk
Shingles, caused by the reactivation of the varicella‑zoster virus (VZV), typically presents as a painful rash with blisters and can lead to long‑lasting nerve pain known as post‑herpetic neuralgia (PHN). Age‑related immune decline makes adults over 50—particularly those with chronic illnesses—significantly more vulnerable.
BUSINESS
Cipla’s Yurpeak gains ground beyond metros as GLP‑1 market accelerates
Strong uptake is visible across Mumbai, Bengaluru, Delhi, Chennai, Hyderabad, Indore and Pune, as well as smaller but fast‑growing centres such as Cannanore, Vijayawada, Aurangabad, Surat, Faizabad and Mangalore—locations where prescriber activation and distribution density are translating into early conversions.
BUSINESS
Nestlé’s $70 billion infant nutrition business faces twin pressures on sugar and safety
Nestlé India confirmed in January that their products are not affected by the global recall of certain infant formula batches due to potential Bacillus cereus contamination. They clarified that all infant formula sold in India is produced locally and complies with FSSAI regulations.
BUSINESS
Eris Lifesciences partners with Natco Pharma to launch semaglutide in India
The collaboration follows Natco’s recent approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture generic semaglutide, setting up a planned launch in March 2026.
BUSINESS
Biocon ramps up biosimilar push, eyes global semaglutide rollout as capex eases
As Shreehas Tambe readies to take charge of the unified Biocon Group following the integration of Biocon Biologics, the company is entering what he calls a “capacity‑rich, demand‑heavy” phase—one where margins improve as capital and R&D intensity taper off.
BUSINESS
Torrent Group enters diagnostics segment with India’s largest reference lab in Navi Mumbai
The 100,000‑sq‑ft lab spans 15 diagnostic disciplines and more than 3,500 test modalities, handling everything from molecular diagnostics and genomics to digital pathology, microbiology and transplant‑related testing.
BUSINESS
CDSCO to get 1,500‑member scientific cadre, will speed up drug approvals
The government has agreed ‘in principle’ to the move and a proposal would be send for approval by March, DGCI Rajeev Singh Raghuvanshi has said
BUSINESS
Will “remove rot of cough‑syrup manufacturing” by next production season: Central drug controller
The regulator has already inspected around 1,150 facilities, or 90% of cough syrup making plants, physically visiting plants and taking enforcement action wherever serious lapses were found.
BUSINESS
Everstone‑backed Integris Medtech gets SEBI nod for IPO
The Everstone Capital–backed company, India’s second‑largest home‑grown diversified medtech platform by FY25 operating revenue, plans to raise up to Rs 925 crore through a fresh issue of shares, alongside an offer for sale of 21.67 million shares from existing investors and founders.
BUSINESS
Miltenyi Biotec sees big India opportunity as it advances Made‑for‑India CAR‑T therapies
Miltenyi is preparing to bring its pipeline of cancer and autoimmune‑targeted therapies to India.
BUSINESS
Dr. Reddy’s preps semaglutide pill launch in FY27, as GLP‑1 market opens up in India
“We are ready with all formats, including the oral,” says M.V. Ramana, CEO of Branded Markets (India & Emerging Markets). Semaglutide is already approved by India’s Subject Expert Committee (SEC), and Dr. Reddy’s is now awaiting the final nod from the national drug regulator, the CDSCO.
